Kling Bio and Sanofi link for antibodies and epitopes discovery
Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes. The partnership…
Immunology
-
-
Sanofi to acquire Vicebio’s share capital for $1.15bn upfront
Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine…
-
FDA approves GSK’s prefilled syringe presentation of Shingrix
The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled…
-
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme, an antibody in…
-
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat…
-
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, a cluster of…
-
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for its…
-
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion…
-
Sobi gains FDA approval for Gamifant to treat HLH/MAS
The US Food and Drug Administration (FDA) has approved Sobi's Gamifant (emapalumab) to treat adults and children with haemophagocytic lymphohistiocytosis…
-
Vor Bio back from brink with autoimmune drug deal rising to $4bn
A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from…
